Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Cash from Operations (2016 - 2025)

Amicus Therapeutics (FOLD) has disclosed Cash from Operations for 16 consecutive years, with 16253000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash from Operations rose 515.04% year-over-year to 16253000.0, compared with a TTM value of 33145000.0 through Dec 2025, up 197.8%, and an annual FY2025 reading of 33145000.0, up 197.8% over the prior year.
  • Cash from Operations was 16253000.0 for Q4 2025 at Amicus Therapeutics, down from 35660000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 35660000.0 in Q3 2025 and bottomed at 80772000.0 in Q4 2022.
  • Average Cash from Operations over 5 years is 21945150.0, with a median of 20520000.0 recorded in 2023.
  • The sharpest move saw Cash from Operations tumbled 229.84% in 2023, then surged 515.04% in 2025.
  • Year by year, Cash from Operations stood at 70514000.0 in 2021, then dropped by 14.55% to 80772000.0 in 2022, then surged by 104.28% to 3458000.0 in 2023, then crashed by 213.24% to 3916000.0 in 2024, then soared by 515.04% to 16253000.0 in 2025.
  • Business Quant data shows Cash from Operations for FOLD at 16253000.0 in Q4 2025, 35660000.0 in Q3 2025, and 26526000.0 in Q2 2025.